Resultados de procura - Saremi, Aramesh
- Mostrando 1 - 20 Resultados de 20
-
1
-
2
-
3
-
4
The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT) por Koska, Juraj, Saremi, Aramesh, Bahn, Gideon, Yamashita, Shizuya, Reaven, Peter D.
Publicado 2013Text -
5
Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration... por Gautier, Thibault, Silwal, Rupesh, Saremi, Aramesh, Boss, Anders, Breton, Marc D.
Publicado 2021Text -
6
-
7
-
8
-
9
-
10
Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study por Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D.
Publicado 2017Text -
11
iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study por Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco
Publicado 2020Text -
12
Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT) por Saremi, Aramesh, Moritz, Thomas E., Anderson, Robert J., Abraira, Carlos, Duckworth, William C., Reaven, Peter D.
Publicado 2010Text -
13
Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance por Hu, Xia, Reaven, Peter D., Saremi, Aramesh, Liu, Ninghao, Abbasi, Mohammad Ali, Liu, Huan, Migrino, Raymond Q.
Publicado 2016Text -
14
Association Between IL-6 and the extent of Coronary Atherosclerosis in The Veterans Affairs Diabetes Trial (VADT) por Saremi, Aramesh, Anderson, Robert J., Luo, Ping, Moritz, Thomas E., Schwenke, Dawn C., Allison, Mathew, Reaven, Peter D.
Publicado 2008Text -
15
Quantification of LVEF≤35% misclassification by 2D-echocardiography as compared to cardiac magnetic resonance in coronary artery disease: implications for AICD therapy por Parrington, Diane J, Saremi, Aramesh, Girotra, Sudhakar V, Dev, Sandesh, Oh, Charles, Scott, Cynthia L, Migrino, Raymond Q
Publicado 2012Text -
16
Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes por Koska, Juraj, Saremi, Aramesh, Howell, Scott, Bahn, Gideon, De Courten, Barbora, Ginsberg, Henry, Beisswenger, Paul J., Reaven, Peter D.
Publicado 2018Text -
17
-
18
Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score... por Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.
Publicado 2019Text -
19
Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Explorat... por Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio
Publicado 2020Text -
20
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors por Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.
Publicado 2012Text